PET-CT Scan for — Triple-Negative and HER2-Positive Breast Cancer

Not automatically. The subtype makes PET-CT a more informative test when it is ordered — triple-negative tumours are metabolically active, so they tend to show up clearly. But the decision to order the scan depends on your stage, not just your subtype. If you have early-stage triple-negative breast cancer, your oncologist will likely treat it without PET-CT, which is consistent with NCCN and ESMO guidance. If your disease is locally advanced, or your team needs to know whether it has spread elsewhere, PET-CT becomes a more useful tool.

No imaging finds every deposit, and PET-CT is no exception. Very small clusters of cells, deposits in certain sites such as the brain, and areas of lower metabolic activity may not appear even when disease is present. What PET-CT adds is a metabolic map of active disease across the whole body in one scan — more than a single CT or bone scan provides on its own. Your team uses it as one source of information, not as a definitive map of everything that is there.

No. Breast cancer is diagnosed by biopsy — a tissue sample examined under a microscope — not by imaging. PET-CT is a staging and assessment tool, used after a diagnosis has been established to understand how extensive the disease is or how it is responding to treatment. An area of high uptake on PET still requires tissue confirmation before treatment decisions are based on it.

It can show whether metabolic activity in the tumour has changed, which is an established way to assess early response — particularly in triple-negative breast cancer receiving neoadjuvant chemotherapy. According to ESMO guidance on imaging in breast cancer, a reduction in tracer uptake after several cycles of treatment is associated with a better pathological response. The final confirmation, however, is the pathology report from surgery. PET shows a metabolic signal, not what the cells look like under a microscope.

No. Not ordering PET-CT for early breast cancer is the correct approach according to international guidelines — not an oversight. The scan adds radiation exposure without changing the treatment plan in early-stage disease. If you are being treated with surgery and systemic therapy at Stage I or II, the absence of a PET scan means your management is guideline-consistent. If you are unsure why a particular test has or has not been ordered, ask your oncologist directly. That is a completely reasonable question and should get a clear answer.

A CT scan shows anatomy — the size and position of visible masses and lymph nodes. A bone scan detects abnormal bone remodelling, which can indicate skeletal spread. PET-CT combines a metabolic map with a structural CT in one sitting, showing both where active disease is and what it looks like anatomically. For metabolically active subtypes like triple-negative and HER2-positive breast cancer, the metabolic information often clarifies findings that a structural scan alone leaves uncertain. Your oncologist chooses between these tests based on the clinical question that needs answering.